ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q2 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,627 | +3.1% | 1,221,838 | -6.5% | 0.00% | – |
| Q1 2023 | $2,548 | -55.4% | 1,306,438 | -12.2% | 0.00% | -100.0% |
| Q4 2022 | $5,711 | -99.9% | 1,487,305 | +24.9% | 0.00% | 0.0% |
| Q3 2022 | $5,740,000 | -63.2% | 1,190,754 | -39.3% | 0.00% | -50.0% |
| Q2 2022 | $15,592,000 | -56.9% | 1,961,210 | -20.4% | 0.00% | -50.0% |
| Q1 2022 | $36,176,000 | -37.2% | 2,462,636 | -13.6% | 0.00% | -20.0% |
| Q4 2021 | $57,599,000 | -25.0% | 2,851,437 | +0.8% | 0.01% | -28.6% |
| Q3 2021 | $76,829,000 | +18.5% | 2,828,740 | +6.2% | 0.01% | +16.7% |
| Q2 2021 | $64,834,000 | -3.3% | 2,662,585 | -3.0% | 0.01% | -14.3% |
| Q1 2021 | $67,025,000 | +6.5% | 2,745,794 | +39.7% | 0.01% | +16.7% |
| Q4 2020 | $62,924,000 | +165.2% | 1,965,761 | +173.3% | 0.01% | +100.0% |
| Q3 2020 | $23,726,000 | -14.4% | 719,175 | +21.4% | 0.00% | 0.0% |
| Q2 2020 | $27,723,000 | – | 592,251 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |